MX364223B - Compuestos de dicarboxamida de benzazepinas. - Google Patents
Compuestos de dicarboxamida de benzazepinas.Info
- Publication number
- MX364223B MX364223B MX2017010895A MX2017010895A MX364223B MX 364223 B MX364223 B MX 364223B MX 2017010895 A MX2017010895 A MX 2017010895A MX 2017010895 A MX2017010895 A MX 2017010895A MX 364223 B MX364223 B MX 364223B
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- diseases
- benzazepine dicarboxamide
- dicarboxamide compounds
- graft
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2015073775 | 2015-03-06 | ||
| CN2015096404 | 2015-12-04 | ||
| PCT/EP2016/054487 WO2016142250A1 (fr) | 2015-03-06 | 2016-03-03 | Composés benzazépine dicarboxamide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017010895A MX2017010895A (es) | 2017-12-15 |
| MX364223B true MX364223B (es) | 2019-04-16 |
Family
ID=55451206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017010895A MX364223B (es) | 2015-03-06 | 2016-03-03 | Compuestos de dicarboxamida de benzazepinas. |
Country Status (32)
| Country | Link |
|---|---|
| US (3) | US9475775B2 (fr) |
| EP (1) | EP3265458B1 (fr) |
| JP (1) | JP6728208B2 (fr) |
| KR (1) | KR102581546B1 (fr) |
| CN (1) | CN107295798B (fr) |
| AU (1) | AU2016231289B2 (fr) |
| BR (1) | BR112017013806B1 (fr) |
| CA (1) | CA2972148C (fr) |
| CL (1) | CL2017002035A1 (fr) |
| CO (1) | CO2017006523A2 (fr) |
| CR (1) | CR20170394A (fr) |
| DK (1) | DK3265458T3 (fr) |
| ES (1) | ES2712488T3 (fr) |
| HK (1) | HK1245766A1 (fr) |
| HR (1) | HRP20190282T1 (fr) |
| HU (1) | HUE042563T2 (fr) |
| IL (1) | IL253170A0 (fr) |
| LT (1) | LT3265458T (fr) |
| MA (1) | MA41625A (fr) |
| MX (1) | MX364223B (fr) |
| MY (1) | MY191185A (fr) |
| PE (1) | PE20171456A1 (fr) |
| PH (1) | PH12017501591A1 (fr) |
| PL (1) | PL3265458T3 (fr) |
| PT (1) | PT3265458T (fr) |
| RS (1) | RS58356B1 (fr) |
| RU (1) | RU2712248C2 (fr) |
| SG (1) | SG11201705732SA (fr) |
| SI (1) | SI3265458T1 (fr) |
| TW (1) | TWI680965B (fr) |
| UA (1) | UA121887C2 (fr) |
| WO (1) | WO2016142250A1 (fr) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107148417B (zh) * | 2014-12-18 | 2020-09-08 | 豪夫迈·罗氏有限公司 | 苯并氮杂*磺酰胺化合物 |
| EP3464245B1 (fr) * | 2016-05-23 | 2020-10-14 | H. Hoffnabb-La Roche Ag | Composés de benzazépine dicarboxamide à fonction amide tertiaire |
| WO2017202703A1 (fr) | 2016-05-23 | 2017-11-30 | F. Hoffmann-La Roche Ag | Composés de benzazépine dicarboxamide à fonction amide secondaire |
| JP7012668B2 (ja) | 2016-06-12 | 2022-02-14 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | ジヒドロピリミジニルベンズアゼピンジカルボキサミド化合物 |
| DK3526323T5 (da) | 2016-10-14 | 2024-09-02 | Prec Biosciences Inc | Modificerede meganucleaser der er specifikke for en genkendelsessekvens i hepatitis b virusgenomet |
| CN110612104A (zh) * | 2017-03-15 | 2019-12-24 | 希沃尔拜克治疗公司 | 苯并氮杂*化合物、缀合物及其用途 |
| CN107311829B (zh) * | 2017-06-06 | 2020-12-11 | 凯莱英生命科学技术(天津)有限公司 | 芳香乙醛类化合物的合成方法 |
| CN107353211A (zh) * | 2017-06-06 | 2017-11-17 | 凯莱英生命科学技术(天津)有限公司 | 烯胺化物的合成方法及芳香醛类化合物的合成方法 |
| WO2019118884A1 (fr) | 2017-12-15 | 2019-06-20 | Silverback Therapeutics, Inc. | Conjugué de construction d'anticorps-médicament pour le traitement de l'hépatite |
| CN111511754B (zh) | 2017-12-20 | 2023-09-12 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸 |
| WO2019123340A1 (fr) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | Dinucléotides 3'3' cycliques ayant une liaison phosphonate activant la protéine adaptatrice de sting |
| JP7050165B2 (ja) | 2018-02-26 | 2022-04-07 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｂｖ複製阻害剤としての置換ピロリジン化合物 |
| WO2019195181A1 (fr) | 2018-04-05 | 2019-10-10 | Gilead Sciences, Inc. | Anticorps et leurs fragments qui se lient à la protéine x du virus de l'hépatite b |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
| WO2020028097A1 (fr) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Formes solides d'acide (r)-11-(méthoxyméthyl)-12-(3-méthoxypropoxy)-3,3-diméthyl-8-0 x0-2,3,8,13b-tétrahydro-1h-pyrido[2,1-a] pyrrolo[1,2-c]phtalazine-7-carboxylique |
| CA3111784A1 (fr) | 2018-09-12 | 2020-03-19 | Silverback Therapeutics, Inc. | Compositions pour le traitement d'une maladie avec des conjugues immunostimulants |
| WO2020056194A1 (fr) * | 2018-09-12 | 2020-03-19 | Silverback Therapeutics, Inc. | Composés de benzazépine, conjugués et utilisations associées |
| AU2019372046B2 (en) | 2018-10-31 | 2022-05-26 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds as HPK1 inhibitors |
| EP3873608A1 (fr) | 2018-10-31 | 2021-09-08 | Gilead Sciences, Inc. | Composés 6-azabenzimidazole substitués ayant une activité inhibitrice de hpk1 |
| JP7287708B2 (ja) | 2019-02-08 | 2023-06-06 | プロジェニア インコーポレイテッド | Ｔｏｌｌ－ｌｉｋｅ受容体７または８アゴニストとコレステロールの結合体およびその用途 |
| JP7350872B2 (ja) | 2019-03-07 | 2023-09-26 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． | ３’３’－環状ジヌクレオチドおよびそのプロドラッグ |
| AU2020231201A1 (en) | 2019-03-07 | 2021-08-26 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
| EP3935065A1 (fr) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | Analogue du dinucléotide 3'3'-cyclique comprenant un nucléotide modifié par cyclopentanyle utilisé en tant que modulateur de sting |
| TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| US11453681B2 (en) | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
| JP7558205B2 (ja) | 2019-06-13 | 2024-09-30 | ボルト バイオセラピューティクス、インコーポレーテッド | 高分子支持アミノベンズアピン化合物 |
| CN114341185A (zh) | 2019-06-19 | 2022-04-12 | 希沃尔拜克治疗公司 | 抗间皮素抗体及其免疫缀合物 |
| JP2022544543A (ja) * | 2019-08-15 | 2022-10-19 | シルバーバック セラピューティックス インコーポレイテッド | ベンザゼピンコンジュゲートの製剤およびその使用 |
| EP4017476A1 (fr) | 2019-08-19 | 2022-06-29 | Gilead Sciences, Inc. | Formulations pharmaceutiques de ténofovir alafénamide |
| CN117843811A (zh) | 2019-09-30 | 2024-04-09 | 吉利德科学公司 | Hbv疫苗和治疗hbv的方法 |
| WO2021067644A1 (fr) | 2019-10-01 | 2021-04-08 | Silverback Therapeutics, Inc. | Polythérapie comprenant des conjugués immunostimulants |
| CN116057068A (zh) | 2019-12-06 | 2023-05-02 | 精密生物科学公司 | 对乙型肝炎病毒基因组中的识别序列具有特异性的优化的工程化大范围核酸酶 |
| WO2021168274A1 (fr) | 2020-02-21 | 2021-08-26 | Silverback Therapeutics, Inc. | Conjugués d'anticorps de nectine-4 et leurs utilisations |
| WO2021177679A1 (fr) | 2020-03-02 | 2021-09-10 | 성균관대학교산학협력단 | Nanoparticules mimétiques d'agent pathogène vivant basées sur un squelette de paroi cellulaire d'agent pathogène, et leur procédé de production |
| AU2021237718B2 (en) | 2020-03-20 | 2023-09-21 | Gilead Sciences, Inc. | Prodrugs of 4'-C-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| EP4175673A1 (fr) | 2020-07-01 | 2023-05-10 | ARS Pharmaceuticals Inc. | Conjugués d'anticorps anti-asgr1 et leurs utilisations |
| US20230355750A1 (en) | 2020-08-04 | 2023-11-09 | Progeneer Inc. | Kinetically acting adjuvant ensemble |
| JP2023536954A (ja) | 2020-08-04 | 2023-08-30 | プロジェニア インコーポレイテッド | 活性化部位が一時的に不活性化したトール様受容体７または８作用薬と機能性薬物の結合体およびその用途 |
| US20230346924A1 (en) | 2020-08-04 | 2023-11-02 | Progeneer Inc. | Mrna vaccine comprising adjuvant capable of kinetic control |
| CN112500347B (zh) * | 2020-12-15 | 2022-03-29 | 成都大学 | 一种苯并氮杂七元环化合物、其制备方法及用途 |
| CA3215049A1 (fr) | 2021-04-10 | 2022-10-13 | Baiteng ZHAO | Agents de liaison a folr1, conjugues de ceux-ci et leurs procedes d'utilisation |
| EP4326768A1 (fr) | 2021-04-23 | 2024-02-28 | Profoundbio Us Co. | Anticorps anti-cd70, leurs conjugués et leurs procédés d'utilisation |
| WO2022241134A1 (fr) | 2021-05-13 | 2022-11-17 | Gilead Sciences, Inc. | Combinaison d'un composé de modulation de tlr8 et agent thérapeutique anti-arnsi de vhb |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| WO2022271659A1 (fr) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Composés modulant les diacylglycérol kinases |
| US11976072B2 (en) | 2021-06-23 | 2024-05-07 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| WO2022271677A1 (fr) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Composés de modulation de la diacylglycérol kinase |
| TW202320857A (zh) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | 連接子、藥物連接子及其結合物及其使用方法 |
| CN118302420A (zh) * | 2021-12-16 | 2024-07-05 | 映恩生物制药（苏州）有限公司 | Tlr调节剂及其用途 |
| CN114181039A (zh) * | 2021-12-23 | 2022-03-15 | 凯美克(上海)医药科技有限公司 | 一种4,4-二苯基-3-丁烯-1-醇的合成方法 |
| TW202411235A (zh) * | 2022-06-02 | 2024-03-16 | 大陸商映恩生物製藥（蘇州）有限公司 | 一種藥物化合物及其用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0582581T3 (da) | 1991-03-01 | 1999-11-08 | Minnesota Mining & Mfg | 1,2-substituerede 1H-imidazo[4,5-c]quinolin-4-aminer |
| US6664265B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
| AU2004315771A1 (en) | 2003-12-04 | 2005-08-25 | 3M Innovative Properties Company | Sulfone substituted imidazo ring ethers |
| TWI404537B (zh) * | 2005-08-19 | 2013-08-11 | Array Biopharma Inc | 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯 |
| US8466167B2 (en) | 2008-03-03 | 2013-06-18 | Irm Llc | Compounds and compositions as TLR activity modulators |
| CA2742863C (fr) | 2008-11-06 | 2017-05-09 | Ventirx Pharmaceuticals, Inc. | Procedes de synthese de derives de benzazepine |
| MX2011008500A (es) | 2009-02-11 | 2011-09-26 | Univ California | Moduladores del receptor tipo toll y tratamiento de enfermedades. |
| JP5759992B2 (ja) | 2009-08-07 | 2015-08-05 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 脂質付加オキソアデニン誘導体 |
| WO2011022509A2 (fr) * | 2009-08-18 | 2011-02-24 | Ventirx Pharmaceuticals, Inc. | Benzoazépines substituées comme modulateurs des récepteurs de type toll |
| WO2011068233A1 (fr) | 2009-12-03 | 2011-06-09 | Dainippon Sumitomo Pharma Co., Ltd. | Imidazoquinolines agissant par l'intermédiaire des récepteurs de type toll (tlr) |
| US20130202629A1 (en) * | 2010-04-30 | 2013-08-08 | The Regents Of The University Of California | Uses of phospholipid conjugates of synthetic tlr7 agonists |
| SG189071A1 (en) | 2010-10-01 | 2013-05-31 | Ventirx Pharmaceuticals Inc | Therapeutic use of a tlr agonist and combination therapy |
| WO2012066336A1 (fr) | 2010-11-19 | 2012-05-24 | Astrazeneca Ab | Composés de benzylamine à titre d'agonistes du récepteur toll-like 7 |
| PT2663555T (pt) * | 2011-01-12 | 2017-03-23 | Array Biopharma Inc | Benzoazepinas substituídas como moduladores de recetores tipo-toll |
| JP6415979B2 (ja) | 2011-06-03 | 2018-10-31 | スリーエム イノベイティブ プロパティズ カンパニー | ヒドラジノ１ｈ−イミダゾキノリン−４−アミン及びこれから調製された複合体 |
| WO2013033345A1 (fr) | 2011-08-30 | 2013-03-07 | Regents Of The University Of Minnesota | Immunomodulateurs et conjugués d'immunomodulateurs |
| AU2012334825B2 (en) | 2011-11-09 | 2017-08-24 | Ascend Biopharmaceuticals Ltd | Immunomodulatory conjugates |
| WO2013166110A1 (fr) | 2012-05-02 | 2013-11-07 | Yale University | Molécules de recrutement d'anticorps conjugués à un agoniste de tlr) |
-
2016
- 2016-03-03 UA UAA201709675A patent/UA121887C2/uk unknown
- 2016-03-03 CR CR20170394A patent/CR20170394A/es unknown
- 2016-03-03 CN CN201680011326.1A patent/CN107295798B/zh active Active
- 2016-03-03 MA MA041625A patent/MA41625A/fr unknown
- 2016-03-03 BR BR112017013806-9A patent/BR112017013806B1/pt active IP Right Grant
- 2016-03-03 WO PCT/EP2016/054487 patent/WO2016142250A1/fr active Application Filing
- 2016-03-03 ES ES16707464T patent/ES2712488T3/es active Active
- 2016-03-03 HU HUE16707464A patent/HUE042563T2/hu unknown
- 2016-03-03 SI SI201630185T patent/SI3265458T1/sl unknown
- 2016-03-03 PL PL16707464T patent/PL3265458T3/pl unknown
- 2016-03-03 CA CA2972148A patent/CA2972148C/fr active Active
- 2016-03-03 EP EP16707464.0A patent/EP3265458B1/fr active Active
- 2016-03-03 DK DK16707464.0T patent/DK3265458T3/en active
- 2016-03-03 RS RS20190221A patent/RS58356B1/sr unknown
- 2016-03-03 KR KR1020177024799A patent/KR102581546B1/ko active IP Right Grant
- 2016-03-03 SG SG11201705732SA patent/SG11201705732SA/en unknown
- 2016-03-03 LT LTEP16707464.0T patent/LT3265458T/lt unknown
- 2016-03-03 PE PE2017001268A patent/PE20171456A1/es unknown
- 2016-03-03 MX MX2017010895A patent/MX364223B/es active IP Right Grant
- 2016-03-03 RU RU2017134866A patent/RU2712248C2/ru active
- 2016-03-03 PT PT16707464T patent/PT3265458T/pt unknown
- 2016-03-03 AU AU2016231289A patent/AU2016231289B2/en active Active
- 2016-03-03 JP JP2017546806A patent/JP6728208B2/ja active Active
- 2016-03-03 MY MYPI2017703228A patent/MY191185A/en unknown
- 2016-03-04 US US15/061,105 patent/US9475775B2/en active Active
- 2016-03-04 TW TW105106788A patent/TWI680965B/zh active
- 2016-09-28 US US15/279,114 patent/US9597333B2/en active Active
-
2017
- 2017-02-14 US US15/432,859 patent/US9822065B1/en active Active
- 2017-06-25 IL IL253170A patent/IL253170A0/en active IP Right Grant
- 2017-06-28 CO CONC2017/0006523A patent/CO2017006523A2/es unknown
- 2017-08-09 CL CL2017002035A patent/CL2017002035A1/es unknown
- 2017-09-04 PH PH12017501591A patent/PH12017501591A1/en unknown
-
2018
- 2018-04-18 HK HK18105008.9A patent/HK1245766A1/zh unknown
-
2019
- 2019-02-12 HR HRP20190282TT patent/HRP20190282T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017501591A1 (en) | Benzazepine dicarboxamide compounds | |
| MX2016013689A (es) | Compuestos 4-amino-imidazoquinolina. | |
| PH12015500323A1 (en) | 2,3-benzodiazepines | |
| MX2015011984A (es) | Inhibidores de bromodominio de dihidro-pirrolopiridinona. | |
| EA201691940A1 (ru) | Новые соединения | |
| PH12018501248A1 (en) | Biprazolyl derivatives useful for the treatment of autoimmune diseases | |
| MD4575C1 (ro) | Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin | |
| PH12016501791A1 (en) | Muscarinic receptor agonists | |
| PH12015500274A1 (en) | Alkylpyrimidine derivatives for the treatment of viral infections and further diseases | |
| UA116648C2 (uk) | Фумарати як проліки та їх застосування при лікуванні різних захворювань | |
| MX2018007319A (es) | Imidazoquinolinas pegiladas como agonistas tlr7 y tlr8. | |
| MX2015008957A (es) | Fluoro-[1,3]oxazinas como inhibidores de beta-secretasa 1 (bace1). | |
| MX2013001970A (es) | Compuestos de pirrolopirimidina y usos de los mismos. | |
| EA201490357A1 (ru) | Индазолы | |
| EA201500383A1 (ru) | Производные 1,2,4-триазина для лечения вирусных инфекций | |
| MX2016007440A (es) | Inhibidores del bromodominio. | |
| PH12015502365B1 (en) | Bace1 inhibitors | |
| EA201700042A1 (ru) | Соединения имидазопиридазина | |
| MX356163B (es) | Anilinas sustituidas como antagonistas de ccr(4). | |
| MX2016005174A (es) | Composiciones para uso en la prevencion y el tratamiento de enfermedades neurodegenerativas y dolor. | |
| MX2015013048A (es) | Forma cristalina de un compuesto ansiolitico. | |
| MX2016006906A (es) | 5-aril-1-imino-1-oxo-[1,2,4]tiadiazinas. | |
| WO2015181837A3 (fr) | Nouveaux composés utilisés comme agents anti-tuberculeux | |
| MX2016016061A (es) | 2,2,2-trifluoroetil-tiadiazinas. | |
| PH12016501808B1 (en) | Chemical compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |